RNAi-based therapies for Huntington’s disease: delivery challenges and opportunities-Reference-Cited by-同舟云学术

RNAi-based therapies for Huntington’s disease: delivery challenges and opportunities

Published:2012-09 Issue:9 Volume:3 Page:1061-1076
ISSN:2041-5990
Container-title:Therapeutic Delivery
language:en
Short-container-title:Therapeutic Delivery

Author:

Mantha Neelima¹,Das Sudip K¹,Das Nandita G²

Affiliation:

1. Department of Pharmaceutical Sciences, College of Pharmacy & Health Sciences, Butler University, Indianapolis, IN 46208, USA

2. Department of Pharmaceutical Sciences, College of Pharmacy & Health Sciences, Butler University, Indianapolis, IN 46208, USA.

Abstract

Huntington’s disease (HD) is a polyglutamine neurodegenerative disease caused by a mutation in the HTT gene coding for the Huntingtin protein (HTT). Unfortunately, there is no cure for HD and there is also no known way to modify the disease progression. RNAi approaches offer the promise of a certain degree of control over the disease. However, there are several challenges in potential use of RNAi in the treatment of HD. This article will discuss the details of RNAi technology as applied to the treatment of HD, and novel approaches to overcome the drug delivery challenges.

Publisher

Future Science Ltd

Subject

Pharmaceutical Science

Link

http://www.future-science.com/doi/pdf/10.4155/tde.12.80

Reference103 articles.

1. HardmanJG, Limberd LL.The Pharmacological Basis of Therapeutics (10th Edition). Hardman JG, Limberd LL (Eds). McGrew Hill, New York, NY, USA (2001).

2. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes

3. Biomolecules under mechanical force

4. Polyglutamine expansion neurodegenerative disease

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Challenges of Using Nanotechnology for Neurological Disorders and Alternate Solutions;Theranostic Applications of Nanotechnology in Neurological Disorders;2023

2. Efficient delivery of Notch1 siRNA to SKOV3 cells by cationic cholesterol derivative-based liposome;International Journal of Nanomedicine;2016-10

3. Transgenic animal models for study of the pathogenesis of Huntington’s disease and therapy;Drug Design, Development and Therapy;2015-04

4. Gene Therapy;Methods and Applications of Statistics in Clinical Trials;2014-09-26

5. Stem cells for cell replacement therapy: A therapeutic strategy for HD?;Movement Disorders;2014-09-12